Login to Your Account


DMD drug launch going well, Sarepta CEO says; Street soundly agrees

By Jennifer Boggs
Managing Editor

Wednesday, January 11, 2017

SAN FRANCISCO – Concerns that launch expectations for Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) might be too ambitious were largely put to rest Tuesday, as CEO Ed Kaye provided updates on patient starts and reimbursement efforts and reported higher-than-expected fourth-quarter revenue.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription